Fibrogen Inc (FGEN): Thomas B Neff , director officer 10% owner (Chief Executive Offic of Fibrogen Inc sold 27,000 shares on May 19, 2016. The Insider selling transaction was reported by the company on May 20, 2016 to the Securities and Exchange Commission. The shares were sold at $17.82 per share for a total value of $477,424.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 18, 2016, K Peony Yu (Chief Medical Officer) sold 6,107 shares at $17.60 per share price.On May 18, 2016, Pat Cotroneo (VP, Finance and CFO) sold 6,107 shares at $17.60 per share price.Also, On May 3, 2016, Thomas B Neff (director officer 10% owner (Chief Executive Offic) sold 27,000 shares at $17.78 per share price.On Apr 4, 2016, Frank H Md Valone (Chief Medical Officer) sold 10,750 shares at $21.29 per share price.
Shares of FibroGen Inc (FGEN) ended Thursday, May 19, 2016 session in red amid volatile trading. The shares closed down -0.45 points or -2.51% at $17.5 with 2,96,964 shares getting traded. Post opening the session at $17.94, the shares hit an intraday low of $17.15 and an intraday high of $18.47 and the price vacillated in this range throughout the day. The company has a market cap of $1,093 M and the number of outstanding shares has been calculated to be 6,24,50,875 shares. The 52-week high of FibroGen Inc is $31.9 and the 52-week low is $14.38.
FibroGen Inc. is a research-based biopharmaceutical company. The Company is focused on the discovery development and commercialization of therapeutic agents. Its lead product candidate is roxadustat or FG-4592 is an oral small molecule inhibitor of hypoxia inducible factor-prolyl hydroxylase (HIF-PHs) in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). The Company’s second product candidate FG-3019 is a monoclonal antibody in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) pancreatic cancer and liver fibrosis. Roxadustat is a HIF-PH inhibitor that acts by stimulating the body’s natural pathway of erythropoiesis or red blood cell production. FG-5200 is a corneal implant. Its product FG-3019 blocks FG-3019 blocks CTGF (CTGF). FG-6874 is a HIF-PH inhibitor. FG-8205 is in preclinical evaluation for use as a cardioprotective agent to prevent the onset of heart failure following a heart attack.